Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34results about "Kallidin/bradykinin ingredients" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
InactiveUS20030087962A1Control inflammationPain controlBiocideKallidin/bradykinin ingredientsArteriolar VasoconstrictionInflammation Process
A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and / or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
Owner:OMEROS CORP
Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
InactiveUS7973068B2Control inflammationPain controlKallidin/bradykinin ingredientsBiocideInflammation ProcessSide effect
A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and / or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
Owner:OMEROS CORP
Antagonists of the bradykinin B1 receptor
InactiveUS20050215470A1Improved pharmacokinetic propertiesKallidin/bradykinin ingredientsSenses disorderMedicineBioactive peptide
The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.
Owner:AMGEN INC
Solvent/polymer solutions as suspension vehicles
A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.
Owner:INTARCIA THERAPEUTICS INC
Modulation of nitric oxide signaling to normalize tumor vasculature
InactiveUS20100087370A1Increase productionHigh expressionKallidin/bradykinin ingredientsGenetic material ingredientsTumor therapyTumor vessel
The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.
Owner:THE GENERAL HOSPITAL CORP
Method of conjugating aminothiol containing molecules to vehicles
InactiveUS20060199812A1High yieldKallidin/bradykinin ingredientsSenses disorderWater solubleOrganic compound
The present invention relates to a novel chemical process that provides novel vehicle derivatives that are exceptional 1,2- or 1,3-aminothiol specific reagents for conjugation to unprotected targeted compounds (e.g., polypeptides, peptides, or organic compounds) having or modified to have a 1,2- or 1,3 aminothiol group. The invention further relates to the methods of using novel water-soluble polymer derivatives and conjugates thereof.
Owner:AMGEN INC
Antagonists of the bradykinin B1 receptor
Owner:AMGEN INC
Use of 5-phosphodiesterase inhibitors to enhance the permeability of the blood-brain barrier of abnormal brain tissue and the blood-tumor barrier
This invention relates to methods and kits for enhancing the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier. Particularly, methods comprising the administration of 5-phosphodiesterase inhibitors, such as sildenafil and vardenafil, to selectively enhance the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier are described. This selective enhancement allows for selective delivery of therapeutic agents or imaging to treat the abnormal brain tissue or a tumor, including brain tumors and non-central nervous system tumors.
Owner:CEDARS SINAI MEDICAL CENT
Methods and compositions for preventing and/or treating pancreatitis
InactiveUS8318657B2Reduce harmKallidin/bradykinin ingredientsBiocideGalanin receptorPancreas Inflammation
The present invention relates to a method of preventing and / or treating pancreatitis in a subject, the method including administering to the subject a therapeutically effective amount of a Galanin antagonist and / or a Galanin receptor antagonist.
Owner:FLINDERS TECH
Methods and compositions for preventing and/or treating pancreatitis
InactiveUS20090081186A1Reducing pancreatic damageReduce harmBiocideOrganic active ingredientsPancreatitisGalanin receptor
The present invention relates to a method of preventing and / or treating pancreatitis in a subject, the method including administering to the subject a therapeutically effective amount of a Galanin antagonist and / or a Galanin receptor antagonist.
Owner:FLINDERS TECH
Histidine-rich glycoprotein
InactiveUS7205392B2Kallidin/bradykinin ingredientsOrganic active ingredientsAngiogenesis growth factorBlood plasma
The invention relates to histidine-rich glycoprotein (HRGP) polypeptides and the use of these polypeptides. The invention includes methods for the inhibition of angiogenesis by administering an HRGP polypeptide. The invention also includes pharmaceutical compositions and articles of manufacture comprising HRGP polypeptides, antibodies and receptors that bind to an HRGP polypeptide, HRGP-depleted plasma and polynucleotides, vectors and host cells that encode HRGP polypeptides.
Owner:INNOVENTUS PROJECT
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
ActiveUS20130136717A1Increasing concentration and half-lifeGood pharmacological propertiesOrganic active ingredientsHormone peptidesBradykinin receptorCvd risk
The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and / or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and / or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Lactone bearing absorbable polymers
The present invention pertains to biodegradable polymers comprising a non-polymerizable lactone, biodegradable compositions comprising the polymer and a therapeutic agent, the use of the compositions for the sustained release of therapeutic agents, wherein the therapeutic agent is reversibly immobilized on the polymer matrix using ionic complexation between the latent carboxylic groups present on the lactone bearing polymer matrix and a cationic group on the therapeutic agent.
Owner:IPSEN PHARMA SAS
Vessel enlargement by arteriogenic factor delivery
A method of delivering an arteriogenic factor. The factor is delivered in a medically effective manner to structurally enlarge an existing blood vessel. A distal portion of a catheter can be advanced to an existing blood vessel to deliver the arteriogenic factor.
Owner:ABBOTT CARDIOVASCULAR
Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders
Bradykinin B1 receptor (B1R) targeting peptides and compounds are radiolabelled with radioisotopes that are suitable for imaging and / or radiotherapy. The radiolabelled peptides and compounds have utility in imaging tissues expressing or overexpressing B1R and / or treating diseases or conditions in which B1R is expressed or overexpressed, including cancer.
Owner:BRITISH COLUMBIA CANCER AGENCY BRANCH
Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels
InactiveUS20060280730A1Easy to practiceKallidin/bradykinin ingredientsBiocideAbnormal tissue growthNon malignant
Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated potassium channel (KCa) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed.
Owner:CEDARS SINAI MEDICAL CENT
Cardiovascular compositions and methods using combinations of anti-platelet agents
InactiveUS20080114025A1Limit their usefulnessLow costBiocideKallidin/bradykinin ingredientsPercent Diameter StenosisMuscle spasm
A method and composition for inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The composition preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also may include anti-restenosis agents.
Owner:OMEROS CORP
Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
ActiveUS9492495B2Increasing concentration and half-lifeGood pharmacological propertiesHormone peptidesOrganic active ingredientsBradykinin receptorAgonist
The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and / or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and / or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Lactone bearing absorbable polymers
InactiveUS20050267280A1Kallidin/bradykinin ingredientsPowder deliveryAbsorbable polymersBiodegradable polymer
The present invention pertains to biodegradable polymers comprising a non-polymerizable lactone, biodegradable compositions comprising the polymer and a therapeutic agent, the use of the compositions for the sustained release of therapeutic agents, wherein the therapeutic agent is reversibly immobilized on the polymer matrix using ionic complexation between the latent carboxylic groups present on the lactone bearing polymer matrix and a cationic group on the therapeutic agent.
Owner:IPSEN PHARMA SAS
Antagonists of the bradykinin B1 receptor
The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
Owner:AMGEN INC
Kinin-based theranostic probes for solid cancers and uses thereof
ActiveUS11213597B2Reduce probabilityKallidin/bradykinin ingredientsKallidins/bradykininsDual imagingPeptide ligand
Owner:SOCPRA SCI SANTE & HUMAINES S E C
Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation
InactiveUS20090253795A1Control inflammationPain controlBiocideKallidin/bradykinin ingredientsArteriolar VasoconstrictionInflammation Process
A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and / or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
Owner:OMEROS CORP
Preparation method of nutrient suitable for blood purification patient and obtained nutrient
PendingCN111956789AImprove malnutritionAvoid healthKallidin/bradykinin ingredientsOrganic active ingredientsBlood plasmaBlood purification
The invention belongs to the technical field of molecular biology, and particularly discloses a preparation method of a nutrient suitable for a blood purification patient and the obtained nutrient. The preparation method of the nutrient comprises the step of carrying out membrane separation on any one of normal human blood, plasma and serum, wherein the pore diameter of an adopted separation membrane is 2-20nm. The components of an ultrafiltrate separated by the separation membrane with the pore diameter are similar to those of substances lost by the blood purification patient in a blood purification process, and experiments prove that when the ultrafiltrate is used as the nutrient to be input into the body of the patient, the malnutrition condition of the blood purification patient can beeffectively improved, particularly the concentration of in-vivo low-molecular-weight protein can be maintained, and the health problem of the blood purification patient at present is effectively solved.
Owner:北京西峰科技有限责任公司
Utilizing the innate immune system to deliver therapeutic agents
PendingUS20220168340A1Enhances endosomal escapePromotes neuronal health and stabilityKallidin/bradykinin ingredientsOrganic active ingredientsInnate immune systemPharmaceutical drug
Owner:DREXEL UNIV
Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.
Owner:TEMPLE OTORONGO LLC
Antagonists of the bradykinin B1 receptor
The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
Owner:AMGEN INC
Lactone bearing absorbable polymers
InactiveUS6955822B1Powder deliveryKallidin/bradykinin ingredientsAbsorbable polymersBiodegradable polymer
The present invention pertains to biodegradable polymers comprising a non-polymerizable lactone, biodegradable compositions comprising the polymer and a therapeutic agent the use of the compositions for the sustained release of therapeutic agents, wherein the therapeutic agent is reversibly immobilized on the polymer matrix using ionic complexation between the latent carboxylic groups present on the lactone bearing polymer matrix and a cationic group on the therapeutic agent.
Owner:IPSEN PHARMA SAS
Nutritional supplement for disinhibiting therapy of psychiatric patients
ActiveUS9072691B2Kallidin/bradykinin ingredientsSulfur/selenium/tellurium active ingredientsAntioxidantKinin
The present invention is a composition and methods of administering the composition to improve a person's mental and physical health by increasing energy levels, motivation, willingness to communicate, appetite, and memory. The composition may be used to treat mental conditions by improving a person's wiliness and ability to communicate. The increase in appetite effect of the composition may be used to treat eating disorders. The composition comprises a carbohydrate, one or more NAD+ / NADP+ producing vitamins, poly-sulfurous chelating agents, vasodilating salts, coenzyme-A producing vitamins, antioxidants, kinins, and biological energy sources.
Owner:SHKLYARENKO LILIYA
Utilizing the innate immune system to deliver therapeutic agents
InactiveUS20200108095A1Promotes neuronal healthImprove stabilityKallidin/bradykinin ingredientsOrganic active ingredientsInnate immune systemPharmaceutical drug
In one aspect, the invention provides a composition comprising at least one monocyte comprising an agent that increases monocyte homing to a site of injury, and an effective amount of a drug. In another aspect, the invention provides a method of using the composition to deliver a drug to a site of injury.
Owner:DREXEL UNIV
Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation
InactiveUS20110160195A1Good treatment effectControl inflammationBiocideKallidin/bradykinin ingredientsInflammation ProcessSide effect
A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and / or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
Owner:OMEROS CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com